NASDAQ · VSTM
Healthcare · Biotechnology
$9.75
Up+$0.09 (+0.93%)
Updated Oct 31, 2026, 7:08 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VSTM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
VSTM closed at $9.75 after 21 trading sessions, up 26.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $9.63 | $9.92 | $9.50 | $9.75 | 2.41M |
| Oct 29, 2026 | $9.85 | $10.03 | $9.54 | $9.66 | 1.94M |
| Oct 28, 2026 | $10.10 | $10.25 | $9.78 | $9.835 | 2.81M |
| Oct 27, 2026 | $9.945 | $10.15 | $9.76 | $10.10 | 4.71M |
| Oct 26, 2026 | $10.00 | $10.1625 | $9.3416 | $10.00 | 4.29M |
| Oct 23, 2026 | $10.085 | $10.22 | $9.71 | $10.04 | 3.76M |
| Oct 22, 2026 | $9.20 | $10.11 | $9.14 | $10.06 | 5.95M |
| Oct 21, 2026 | $9.41 | $9.67 | $9.12 | $9.21 | 3.06M |
| Oct 20, 2026 | $8.62 | $9.4701 | $8.57 | $9.34 | 3.96M |
| Oct 19, 2026 | $8.58 | $9.17 | $8.51 | $8.62 | 3.4M |
| Oct 16, 2026 | $9.235 | $9.37 | $8.53 | $8.65 | 6.09M |
| Oct 15, 2026 | $8.04 | $9.73 | $7.77 | $9.23 | 16.96M |
| Oct 14, 2026 | $8.00 | $8.955 | $6.70 | $7.71 | 33.76M |
| Oct 13, 2026 | $8.15 | $8.20 | $7.445 | $7.45 | 3.43M |
| Oct 12, 2026 | $8.42 | $8.60 | $8.075 | $8.25 | 3.58M |
| Oct 9, 2026 | $8.12 | $8.58 | $7.98 | $8.38 | 2.97M |
| Oct 8, 2026 | $8.20 | $8.28 | $7.72 | $8.11 | 3.05M |
| Oct 7, 2026 | $7.77 | $8.355 | $7.65 | $8.265 | 3.93M |
| Oct 6, 2026 | $8.08 | $8.18 | $7.695 | $7.75 | 2.51M |
| Oct 5, 2026 | $7.74 | $8.10 | $7.52 | $8.00 | 2.22M |
| Oct 2, 2026 | $7.95 | $8.015 | $7.52 | $7.70 | 4.07M |
The latest Smart Investors Daily articles mentioning VSTM.
Company
Market Activity
Research & News
VSTM research
Company profile and research snapshot.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | BTIG | Buy | — |
| Oct 16, 2026 | Mizuho | Outperform | — |
| Oct 15, 2026 | RBC Capital | Outperform | — |
| Oct 15, 2026 | Jefferies | Buy | — |
| Oct 15, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 24, 2026
Verastem Oncology reported initial multi tumor data from its TARGET D 101 Phase 1/2 trial, showing robust clinical activity and a favorable safety and tolerability profile for VS-7375 across KRAS G12D-mutated pancreatic, colorectal and lung cancers, and aligned with the FDA on a first line pancreatic Phase 3 design. The depth of responses at the 900 mg once daily dose, including high objective response rates, molecular clearance of KRAS G12D circulating tumor DNA and low treatment...
Yahoo · Oct 22, 2026
BOSTON, October 22, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET.
SeekingAlpha · Oct 20, 2026
Incyte Corporation shares ESMO 2026 highlights: KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOEâclick for more on INCY stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VSTM.
